Skip to main content

Table 4 The transplantation of stem cells from adult tissues in the POF animal model

From: Comparison of the different animal modeling and therapy methods of premature ovarian failure in animal model

Stem cell types

POF model

The transplantation of stem cells from adult tissues

Stem cell from references

Animal

Drug

Stem Cells

Treatment

Main effects of stem cell on POF

Mechanism

BMSCs

Rats (5 weeks)

CTX

(1st, 50 mg/kg, 8 mg/kg for 14 days)

BMSCs

(1 × 106 cells) in 100μL PBS for 2w

iv

Increase E2 and AMH, decrease FSH level;

Recover the estrous cycle;

Increase the number of basal and sinus follicles

BMSC-derived exosome Mir-144-5p has a protective effect on the apoptosis of CTX-damaged OGCs

[23]

Rats

(3 weeks)

3.2 Gy radiotherapy (0.48 Gy/min)

BMSCs

(2 × 106 cells) in 150μL PBS

iv

Enhances ovarian follicles;

Increases serum estradiol- and follicle-stimulating hormone levels;

Restores fertility

Upregulates Wnt/β-catenin and Hippo signaling pathways

[59]

Exosome from BMSCs

Mice

(6–7 weeks)

CIS (5 mg/kg)

BMSCs-Exos

(125 μg dissolved in 100 μL PBS

iv

Inhibit OGCs apoptosis;

Increase E2;

delivering miR-644-5p to granulosa cells to regulate p53 expression of cells

[60]

Rats (5 weeks)

CTX

(1st, 50 mg/kg, 8 mg/kg for 14 days )

BMSCs-Exos (150 μg dissolved in 100 μL PBS; every other day for 2 weeks)

iv

Decrease FSH and LH, increase AMH, E2;

Inhibit OGCs apoptosis;

Exosomes miR-144-5p inactivated the PI3K/AKT pathway by suppressing PTEN targeting

[23]

ADMSCs

Rats

CTX

(120 mg/kg)

ADMSCs

(1 × 106 cells, passages 3–4)

Ip

Increase the number of primordial follicles and decrease the number of atretic follicles;

Increase AMH level;

Inhibit the apoptosis of follicle

Regulate the expression of Connexin43 and pAnnexin1

[61]

Exosome from ADMSCs

Mice (7–8 weeks)

CTX

(120 mg/kg for 2 weeks)

hADSC-Exos

(1 × 106 cells, cocultured with hGCs)

Ip

Attenuate ovary damage;

Increase the number of follicles;

Enhanced the E2 and AMH levels and decreased the FSH levels;

Inhibit OGCs apoptosis

Increase expression of SMAD2, SMAD3, and SMAD5 in vivo and in vitro

[62]

HuMenSCs

Mice (7–8 weeks)

CIS

(2 mg/kg for 7 days )

HuMenSCs (2 × 106/mL) in 200 μL PBS

iv

Increase body and ovary weight;

Increase the number of follicles;

Reduce OGCs apoptosis; repair ovarian injury,

Stimulate regeneration, and improve ovarian function

Protects damaged ovaries by secreting FGF2

[63]

Rats (8 weeks)

BF

(36 mg/kg)

HuMenSCs

(Passages 3)

iv

Improve follicle development;

Promote AMH and E2 secretion

NO Report

[64]

Rats (6–8 weeks)

BF

(36 mg/kg)

HuMenSCs

(1 × 106 cells per 200 μL) in 1 mL PBS

iv

Increased body and ovary weight;

Increase the number of follicles;

Reduce OGCs apoptosis

NO Report

[58]

Mice (18–19 g)

CTX

(120 mg/kg) + BF (30 mg/kg)

hEnSCs

(2 × 106 cells, passages 5) in 20 μL PBS

Orthotopically inject

Increased body weight;

Improved estrous cycles;

Restored fertility

Reduce chemotherapy-induced depletion of the germline stem cell pool

[57]

  1. BMSCs bone marrow mesenchymal stem cells, ADMSCs adipose-derived mesenchymal stem cells, HuMenSCs human menstrual-derived stem cells